These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 22237037

  • 1. Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study.
    Liang FY, Sun W, Han P, Lu X, Lian YN, Huang XM.
    Chin J Cancer; 2012 Mar; 31(3):142-9. PubMed ID: 22237037
    [Abstract] [Full Text] [Related]

  • 2. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY, Twu CW, Lin WY, Jiang RS, Liang KL, Chen KW, Wu CT, Shih YT, Lin JC.
    Cancer; 2011 Oct 01; 117(19):4452-9. PubMed ID: 21437892
    [Abstract] [Full Text] [Related]

  • 3. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Paramita DK, Fachiroh J, Adham M, Tan IB, Haryana SM, Middeldorp JM.
    Int J Cancer; 2006 Aug 01; 119(3):608-14. PubMed ID: 16572427
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF, Zhang Y, Huang XB, Du XJ, Tang LL, Chen L, Peng H, Guo R, Sun Y, Ma J.
    Chin J Cancer; 2017 Nov 07; 36(1):87. PubMed ID: 29116021
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB, Zhang N, Chen DM, Yang XL, Chen BH, Zhao H, Lu RL, Chen Y, Fu LW.
    Radiother Oncol; 2019 Mar 07; 132():223-229. PubMed ID: 30366725
    [Abstract] [Full Text] [Related]

  • 6. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL, Sun XS, Li XY, Tang LQ, Chen QY, Lin HX, Liang YJ, Yan JJ, Lin C, Guo SS, Liu LT, Li Y, Xie HJ, Tang QN, Liang H, Guo L, Mai HQ.
    Cancer Commun (Lond); 2019 Mar 29; 39(1):14. PubMed ID: 30925939
    [Abstract] [Full Text] [Related]

  • 7. Differentiation of recurrent nasopharyngeal carcinoma and skull base osteoradionecrosis by Epstein-Barr virus-derived latent membrane protein-1 gene.
    Hao SP, Tsang NM, Chang KP.
    Laryngoscope; 2001 Apr 29; 111(4 Pt 1):650-2. PubMed ID: 11359135
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF, Huang QH, Yu X, Liu Z, Li X, Zhang LF, Wang P, Xie SH, Rao HL, Fang F, Guo X, Liu Q, Hong MH, Ye W, Zeng YX, Cao SM.
    Cancer; 2014 May 01; 120(9):1353-60. PubMed ID: 24477877
    [Abstract] [Full Text] [Related]

  • 9. Early detection of nasopharyngeal carcinoma: performance of a short contrast-free screening magnetic resonance imaging.
    King AD, Ai QYH, Lam WKJ, Tse IOL, So TY, Wong LM, Tsang JYM, Leung HS, Zee BCY, Hui EP, Ma BBY, Vlantis AC, van Hasselt AC, Chan ATC, Woo JKS, Chan KCA.
    J Natl Cancer Inst; 2024 May 08; 116(5):665-672. PubMed ID: 38171488
    [Abstract] [Full Text] [Related]

  • 10. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
    Hong RL, Lin CY, Ting LL, Ko JY, Hsu MM.
    Cancer; 2004 Apr 01; 100(7):1429-37. PubMed ID: 15042677
    [Abstract] [Full Text] [Related]

  • 11. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.
    Chan JY, Wong ST.
    Laryngoscope; 2014 Jan 01; 124(1):126-30. PubMed ID: 23686740
    [Abstract] [Full Text] [Related]

  • 12. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
    Chan KC, Hung EC, Woo JK, Chan PK, Leung SF, Lai FP, Cheng AS, Yeung SW, Chan YW, Tsui TK, Kwok JS, King AD, Chan AT, van Hasselt AC, Lo YM.
    Cancer; 2013 May 15; 119(10):1838-44. PubMed ID: 23436393
    [Abstract] [Full Text] [Related]

  • 13. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T, Tang LQ, Luo DH, Chen QY, Li PJ, Mai DM, Guo SS, Liu LT, Qian CN, Guo X, Zeng MS, Mo HY, Mai HQ.
    PLoS One; 2015 May 15; 10(4):e0122756. PubMed ID: 25853677
    [Abstract] [Full Text] [Related]

  • 14. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
    Wei WI, Yuen AP, Ng RW, Ho WK, Kwong DL, Sham JS.
    Head Neck; 2004 Oct 15; 26(10):878-83. PubMed ID: 15390201
    [Abstract] [Full Text] [Related]

  • 15. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 16. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma.
    King AD, Woo JKS, Ai QY, Chan JSM, Lam WKJ, Tse IOL, Bhatia KS, Zee BCY, Hui EP, Ma BBY, Chiu RWK, van Hasselt AC, Chan ATC, Lo YMD, Chan KCA.
    Ann Oncol; 2019 Jun 01; 30(6):977-982. PubMed ID: 30912815
    [Abstract] [Full Text] [Related]

  • 17. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ, Fang SG, Huang W, Wang HY, Tian YM, Huang RD, Sun Z, Zhao C, Lu TX, Huang Y, Han F.
    Cancer Med; 2019 Aug 01; 8(10):4633-4643. PubMed ID: 31268626
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC.
    J Clin Pathol; 2006 May 01; 59(5):537-41. PubMed ID: 16489178
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis and management of skull base osteoradionecrosis after radiotherapy for nasopharyngeal carcinoma.
    Huang XM, Zheng YQ, Zhang XM, Mai HQ, Zeng L, Liu X, Liu W, Zou H, Xu G.
    Laryngoscope; 2006 Sep 01; 116(9):1626-31. PubMed ID: 16954993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.